chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Pain to left arm. Redness from shoulder to elbow. Migraine headache. Fever to 101.4. Nausea. Unable to eat. General body ache. Started 24 hours after receiving vaccine. Fever treated with ibuprofen. Obtain relief for about 4 hrs, then fever returns. Been three days now still sick.
Eyeballs red as fire Left alone; eventually faded. Tired, in bed for 3day wkend. Day wknd (9, 10, 11, 12)
Bell's Palsy, right side facial droop, facial tingling, and feeling of facial fullness on 1/25/21.
some of the vaccine leaked out onto the patient's arm; some of the vaccine leaked out onto the patient's arm; some of the vaccine leaked out onto the patient's arm; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete dose administered in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete dose administered, inadvertent exposure to vaccine and exposure via skin contact. On an unknown date, the outcome of the incomplete dose administered, inadvertent exposure to vaccine and exposure via skin contact were unknown.   Additional Information: GSK Receipt Date: 06-July-2022. Reporter's Comments: The reporter mentioned that while administering a dose of Shingrix some of the vaccine leaked out onto the patient's arm. The reporter consented to follow up. The lot and expiration date but it was deleted during updation of another field by reporter. The Vaccine Administration Facility was the same as Primary Reporter. Additional Supportive Information: The vaccine leaked out onto the patient's arm, which led to inadvertent exposure to vaccine, exposure via skin contact and incomplete dose administered.
7cm x 4.5cm erythematous patch at site of injection on left upper arm.  Left earache, nasal congestion, pain and pruritus at injection site.
Within a week of the vaccine patient started having sharp pains in both feet and legs.   It is not in a specific part of the foot, it is in the entire foot.  Feet are much worse than legs.  Pain in legs in localized to calf muscle and travels up the leg.  Foot pain involves the arch of the foot, toes, padding off foot.  Type of pain fluctuates between sharp and dull but is usually sharp.  Foot numbness and tingling also present.  Within the past two weeks patient is now getting burning, numbness and pain in her middle and pointer finger in the left hand.  Patient is left handed.  Patient recently sought care from a podiatrist who recommended a dose pack but is not sure anything will help with this pain.  He recommended she start an over the counter supplement called  NeuRX-TF  which has made a very minor difference in symptoms.  She is scheduled to see a neurologist this upcoming week.  It is also important to note that the patient was covid positive in December.  During this time she had sharp pains in her feet, legs and entire body aches.   Pain in her feet did resolve as her condition improved from the virus during its normal course of recovery.
After 2023-24 Moderna spikevax 12+ booster. Unclear whether related or not, but my migraines are quite rare. 1.5 days after the booster, I had a blindspot form in center of vision at 7:45pm - gradually expanding in a jagged circle outward, lasting 1 hour.  Slight tightness mild pain pressure on sides of head as this went on.  The timing strikes me as at least suspicious. I informed a neurologist who agreed that it can trigger migraine, but also not necessarily.
Day after vaccination developed right sided facial droop with tinnitus on right side, testing revealed 5-10 decibel drop in hearing in mid to high range compared to the left.  Otherwise neurologically normal by history and examination.
Information has been received from a pharmacist referring to a patient of unknown age. Information about concurrent condition, concomitant medication and medical history was not provided. On 12-OCT-2016, the patient was inadvertently vaccinated with an expired dose of PNEUMOVAX 23 (lot # K010522, expiration date: 25-FEB-2016) (0.5 ml/once) intramuscularly. No adverse effects were reported. The outcome of the events was unknown. Additional information has been requested.
6/1/19 in the p.m., lymph nodes behind her ears and up the base of her skull began to swell. On 6/2/19 in the a.m. lips swelled slightly. Also had slight fever of 97 degrees (high per client). Client went to ED on 6/2 in early a.m. Discharged with Benadryl and diagnosis of lymphadenopathy. She was told to return if condition worsened or go to PCP. On 6/3 in the evening, she noticed a mild rash on her forehead. On 6/4 in the a.m. rash had spread to her face. Client plans on PCP visit next week, earlier if symptoms worsen.
After the second dose it was a little bit itchy around the injection site; This spontaneous case was reported by an other health care professional and describes the occurrence of VACCINATION SITE PRURITUS (After the second dose it was a little bit itchy around the injection site) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 029L20A and 039K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PRURITUS (After the second dose it was a little bit itchy around the injection site). At the time of the report, VACCINATION SITE PRURITUS (After the second dose it was a little bit itchy around the injection site) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.  All 3 were injections on her right arm, she is left handed.  Concomitant medications were not provided.  Treatment information was not provided.   This case was linked to MOD-2021-375229 (Patient Link).
Information has been received from a registered nurse concerning a newborn male who at birth, on approximately 8/16/02, was vaccinated with the first dose of hepatitis B vaccine recombinant (yeast). Within 30 minutes post vaccination, the patient experienced apnea, a drop in blood pressure and loss of responsiveness, for a couple of minutes. Unspecified medical attention was sought. At the time of report, 8/16/02, it was reported that the child is one month old now. On 9/18/02, the physician's office received a request for a referral for the child to see an allergist, due to the severe reaction that the child had to hepatitis B. That same day, it was reported that the child is now fine. The hospital discharge summary had not been received by the office, at the time of report. Upon internal review, apnea, blood pressure drop, and loss of responsiveness were determined to be other important medical events. Additional information has been requested. This is in follow-up to report previously submitted on 9/20/02. Information has been received from a health professional concerning a 3 day old hospitlaized female who was vaccinated on 8/13/02 at 11:20am in the left thigh IM with a first dose of hep B vaccine recombinant (lot 642479/0034M). There were no concomitnat medications. On 8/13/02 at 12:35pm (also reported as within 30 minutes post-vaccination) the pt developed severe peripheral cyanosis, stridor, laryngospasm, loss of muscle tone, apnea, a drop in blood pressure, and loss of responsiveness, lasting a couple of minutes. The pt maintained an oxygen saturation of greater than 97% on room air and was asymptomatic without any treatment approximately 30 minutes after onset of symptoms. It was reported that these events resulted in a prolonged hospitalization. On 9/18/02, the physician's office received a request for a referral for the child to see an allergist, "due to the severe reaction that the child had to hep B." That same day, it was reported that the child is "now" fine. On 10/1/02, the pt was reported as recovered. No further info is expected.
This spontaneous report as received from a medical assistant refers to a patient of unknown demographics. The patient's current conditions or medical history were not reported. On 27-MAR-2014, the patient was vaccinated with a dose of VARIVAX inj 0.5 ml subcutaneous (lot number and expiration date were not provided) that was stored outside of the prescribing information. No adverse effects were reported. Additional information has been requested.
Pt Got covid19 vaccine dose #2 at 1230pm into Lt deltoid, it hurt immediately like an extra punch as it was being removed. Sore there from that time and more and more sore, soreness went to rest of body; back and legs are killing her. Headache and chills off and on. Feels feverish.  No vomiting. No diarrhea. No sob. No coughing. Likely a vaccine reaction.   Rx taking: thrive vitamins. Sertraline last does was a week prior. 25 mg.   She has no hx of other vaccine reactions.
Fever Cold like symptoms Abnormal high BP (normal BP is 114/68, BP registered st emergency room at 148/90) Dizzy spells Lightheaded Fainting Struggling to eat and drink Diarrhea
Client reported onset of redness and swelling at 1400, 8-27-2009. Presented to Health Dept 8-27-2009 at 1550 within 40 to 35 min redness, swollen arm right posterior upper arm. No other symptoms.
pt to ED with garbled speech, left upper and lower extremity weakness; admitted to hosp; A Fib with RVR; CVA; found to be positive for COVID; COVID pneumonia; pt refused anticoagulation; increase in O2 requirements; started on dexamethasone; developed fever, leukocytosis, and a decrease in her mental state; sepsis; given ABX; transferred to ICU; pt worsened and developed a sudden bradycardia then no pulse; DNR; pt died in the hospital
Varicella -Information has been received from a consumer concerning her 31 month old Caucasian son who on 28 Jan 1999 was vaccinated with a first dose of varicella virus vaccine live SC in the thigh.  concomitant vaccinations that same day included a fourth dose of diphtheria toxoid (-) pertussia vaccine (+) tetanus toxoid lot number 457-788, IM in the thigh and a third dose of oral poliovirus vaccine lot number 456917.  On 14 Mar 2000, the patient developed a case of chickenpox.  The child's mother stated that he was very ill.  had a fever for several days, and pox.  in his mouth and ears.  He did not sleep for three nights until medical attention was sought and a pedicatrician prescribed a strong antihistamine.  Follow up information from a physician's office indicated that the patient did not have any pre-existing allergies or medical conditions.  No further information is available.
got COVID 2-3 weeks after receiving a dose of the COVID-19 vaccine bivalent version; got COVID 2-3 weeks after receiving a dose of the COVID-19 vaccine bivalent version; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team and product quality group.  A patient (no qualifiers provided) received BNT162b2, BNT162b2 OMI ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 5 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "got COVID 2-3 weeks after receiving a dose of the COVID-19 vaccine bivalent version".  The information on the batch/lot number for BNT162b2, BNT162b2 OMI ba.4-5 has been requested and will be submitted if and when received.  Amendment: This follow-up report is being submitted to amend previously reported information: Removed patient information from patient tab as reporter is not a patient and updated dose description of third and fourth dose COVID-19 vaccine.  Follow-up (01Dec2022): This is a follow-up report to notify that  case 202201300085 and case 202201345851 are duplicates.  All subsequent follow-up information will be reported under Manufacturer report number 202201345851.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202201300194 same reporter/vaccine/event, different patients;US-PFIZER INC-202201300196 same reporter/vaccine/event, different patients;US-PFIZER INC-202201300195 same reporter/vaccine/event, different patients;US-PFIZER INC-202201300197 same reporter/vaccine/event, different patients;US-PFIZER INC-202201307472 same reporter/vaccine, different events/patients;
Patient is under 18 years old and received a booster dose. Will be reaching out to family to make them aware of error and also make a note in the online portal.
mild shoulder/neck stiffness; arm sore; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 48 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 16Mar2021 08:45 (Lot number: EN6200) at the age of 48 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "hypothyroid" (unspecified if ongoing); "severe abd pain" (unspecified if ongoing); "Chia seed allegy" (unspecified if ongoing); "anaphylaxis" (unspecified if ongoing); "Latex" (unspecified if ongoing); "rash" (unspecified if ongoing), notes: known allergies: Sesame seeds, severe abd pain,, allergy verified by blood test. Concomitant medication(s) included: LEVOTHYROXINE SODIUM; LYSINE; VITAMIN D NOS; MULTIVITAMIN [VITAMINS NOS]. The following information was reported: MUSCULOSKELETAL STIFFNESS (non-serious) with onset Mar2021, outcome "unknown", described as "mild shoulder/neck stiffness"; PAIN IN EXTREMITY (non-serious) with onset Mar2021, outcome "unknown", described as "arm sore". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of musculoskeletal stiffness, pain in extremity.  Additional information: known allergies: Sesame seeds, severe abd pain,, allergy verified by blood test. Chia Seeds: anaphylaxis. Latex: rash and allergy verified by blood test. It was reported that the facility where the most recent COVID-19 vaccine was administered in Hospital. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. List of any other medications the patient received within 2 weeks of vaccination was Levothyroxine, Lysine, Vitamin D, Multivitamin. The patient was not diagnosed with COVID-19 prior to vaccination Since the vaccination the patient was not tested for COVID-19. The patient reported Event with 1st dose, mild shoulder/neck stiffness, arm sore, not bad.  No follow-up attempts are possible. No further information is expected.
shingles; This is a spontaneous report from a contactable consumer (patient) Pfizer Sponsored Program.  A 34-year-old Female consumer received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) on 18Dec2020 at 08:45 at single dose in right arm for COVID-19 immunisation at the age of 34-year-old. Lot number was EJ1685. Medical history included ongoing epilepsy. Concomitant medications included ongoing carbamazepine (TEGRETOL) for epilepsy. On 06Jan2021, the patient had shingles. The consumer was provided with medication, VALTREX and she was informed to take it at 1mg three times a day. The consumer was calling because she needed to know if she could get her second dose as she was scheduled to receive it on 08Jan2021. The patient did not recover from the event. Information on the lot/batch number has been requested.
Cellulitis, fever. Left arm, redness, tenderness & swelling to lateral deltoid with several red macules on skin. DEPO MEDROL 80mg IM given 7-15-11 (1311).
I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 8/31/2022 CHEST PAIN I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 8/31/2022 ACUTE GASTRIC ULCER I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 8/31/2022 ATRIAL FIBRILLATION, UNSPECIFIED
This spontaneous report was received from a pharmacist refers to a patient of unkonwn demographics. No relevant medical history of the patient was reported. On 06-AUG-2014 the patient was vaccinated with PNEUMOVAX 23 (lot # J006242, expiration date: 03-AUG-2014), 0.5 ml, intramuscular. There were no concomitant medications reported. On 06-AUG-2013 the patient received a dose of PNEUMOVAX 23 3 days after the expiry (03-AUG-2014). The patient experienced no adverse effects. There was no product quality complaint (PQC) involved. The outcome was unknown. Additional information has been requested.
Generalized arm pain after injection, severe fever, chills, brain fog, swollen lymph nodes, severe fatigue. Symptoms were most severe for 18 hours after shot. Swollen lymph nodes and severe fatigue continued for two weeks post shot.
Fatigue; This is a spontaneous report received from a contactable reporter(s) (Other HCP).  A 57 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date Mar2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Prior to vaccination, the patient was not diagnosed with COVID-19. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The following information was reported: FATIGUE (non-serious) with onset Mar2021, outcome "recovered" (Mar2021), described as "Fatigue". Therapeutic measures were not taken as a result of fatigue.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
biceps tendonitis at injection site; This case was reported by a consumer via call center representative and described the occurrence of tendonitis in a adult patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingrix. In October 2019, unknown after receiving Shingrix, the patient experienced tendonitis. On an unknown date, the outcome of the tendonitis was not recovered/not resolved.   It was unknown if the reporter considered the tendonitis to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The age group was not reported but it was selected as adult as per the vaccine indication. The patient received Shingrix had been experiencing bicep tendonitis since October. The reporter asked could this condition had been a result of this procedure. The condition was near the area where the injection was placed.
Information has been received from a physician concerning a male who on 05-APR-2007 was vaccinated with a single dose of Zostavax. On 14-APR-2007 (also reported as 17-APR-2007) the patient experienced "encephalitis" and was hospitalized. It was reported that the patient was air lifted to a hospital and was in the ICU. There was no product quality complaint involved. No further information. Additional information has been requested. 5/1/07 T/C to reporter to request missing info.  Received patient demographics.   6/15/07 Received provider medical records which included vax lot #.  VAERS database updated.  Seen in PCP office on 4/5/07 for diet consult re diabetes, wt 301.  left inguinal hernia & possible right hand CTS noted.  8/21/07 Received hospital medical records which reveal patient experienced unresponsiveness while at home.  Out of state daughter called EMS when no response.  Daughter stated patient had c/o stiff neck, sour stomach, weakness & febrile to 104  since zostavax on 4/5/07.  Found to be unresponsive w/rash on abdominal area.  Glucose was 326.  Intubated & helicoptered to ER.  Admitted 4/14-5/14/07.  Found to be in acute renal failure secondary to rhabdomyolysis & hypotension.  Tx w/hemodialysis, pressors, antivirals & antibiotics.  Nephrology, neurology & ID consults done.  Trached & weaned to trach collar oxygen, feeding tube placement.  Weaned from hemodialysis & renal function slowly improving.  Remained in comatose state w/poor prognosis at transfer.  FINAL DX: viral meningitis, anoxic brain injury. 7/25/08-ventricular arrhythmia. arteriosclerotic cardiovascular disease. 1/4/2010 My brother died Oct 13, 2007. There were mistakes performed in medical center which caused him to go without 02 for 15 minutes. He was only minimaly conscious after that point.
Information has been received from a nurse concerning a 14 year old female who on 18-OCT-2007 was vaccinated IM with the first dose of GARDASIL.  On 30-OCT-2007, the patient was vaccinated IM with the second dose of GARDASIL and on 14-MAR-2008, the patient was vaccinated IM with the third dose of GARDASIL.  The patient reported pain in the arm at the injection site for 3 days after the vaccination was given.  The pain in the arm included not being able to lift the arm.  The nurse also reported that since multiple patients (3 patients) reported pain in their arms, they started giving the vaccination in the buttocks to an unspecified number of patients.  Unknown medical attention was sought through contact with the nurse.  Patient outcome was unknown.  No product quality complaint was involved.  This is one of the multiple cases from the same source (WAES # 0804USA05546 and 0805USA01521).  Additional information has been requested.
Patient had trouble breathing after vaccination. Assessed by on-site EMT who determined she could return to home.
the patient inadvertently received MMR II via the intramuscular route instead of the intended subcutaneous route; no adverse effects; This spontaneous report as received from a pharmacist concerning to a patient of unknown age and gender. The patient's historical condition, concomitant medications and drug reactions or allergies were not reported.        On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) lot # R019684 and expiration date 09-JUL-2020, intramuscular for prophylaxis (dosage schedule, route, anatomical location were not reported). Additionally,  the patient was inadvertently received a dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II)  via the intramuscular route instead of the intended subcutaneous route (incorrect route of product administration). No adverse effects reported.
01/18/22 presents to ED for "epigastric abdominal pain". PMHx of "CAD, HTN, alcohol abuse"
pt recv vax 27JAN98 & pt crabby;pt was crying hysterically;pt became purple & limb & no longer crying;pt taken to MD EEG done pt may have had sz but no med unless sz so little recommended no pertussis;
Patient received 1st dose 9 months ago and still didn´t received the 2nd dose; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 81-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose 9 months ago from reporting).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 28-Jun-2022 The reporter stated that patient received their only one dose of Shingrix 9 months ago and still did not receive the 2nd dose. The reporter did not consent to follow up. Additional supportive information: Till the time of reporting, the patient did not received 2nd dose which led to incomplete course of vaccination.